LUCENTIS - Ranibizumab InjectionLines gained. Lives changed.
For US Healthcare Professionals Only

About Ranibizumab|Mechanism of Action

LUCENTIS is proven to quickly and completely penetrate all layers of the retina, as demonstrated in animal studies1

  • LUCENTIS facilitates VEGF-A suppression throughout retinal and choroidal layers while minimizing systemic exposure to the drug2
  • LUCENTIS rapidly reaches beneath the retina to treat the choriocapillaris choroidal layers where choroidal neovascular (CNV) lesions originate in wet AMD1
Tools & Resources

Get information on conferences, events, and how to order LUCENTIS and other materials for your patients.

LUCENTIS Resources 
LUCENTIS Access Solutions™

Helps resolve access and reimbursement issues for patients. Our specialists help patients gain access to LUCENTIS while supporting your practice throughout the reimbursement process.

Visit LUCENTIS Access Solutions 
LUCENTIS Direct

With LUCENTIS Direct, you can order LUCENTIS straight from Genentech. It’s friendly service and fast, overnight delivery.

Visit the Web site 
Call Us
Get more information on LUCENTIS at:
1.866.LUCENTIS
(1.866.582.3684)
Monday-Friday
9 AM-8 PM ET


INDICATION

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.

Although there was a low rate (<4%) of arterial thromboembolic events (ATEs) observed in LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of inhibitors of VEGF.

Serious adverse events related to the injection procedure occurring in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. Other serious ocular events occurring in <2% of patients included intraocular inflammation with or without hypersensitivity and increased IOP.

In clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, and vitreous floaters. Most common nonocular side effects included nasopharyngitis, headache, respiratory and urinary tract infections.

LUCENTIS is for prescription use only.

Individual results with LUCENTIS may vary.

Please see LUCENTIS full Prescribing Information 
Disclaimer

By selecting this link, you will be leaving www.LUCENTIS.com and going to a site that is not controlled by or affiliated with Genentech USA, Inc. Genentech is neither affiliated with nor endorses any of the aforementioned organizations. The information provided by Genentech or these organizations is meant for informational purposes only and is not meant to replace your doctor’s medical advice.